Breast Cancer Clinical Trials in Boston

Showing 81-100 of 295 trials

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

NCT03501979

A phase 2 non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab with capecitabine for the treatment of leptomeningeal metastases in HER2-neu positive breast cancer.

Metastatic Breast CancerLeptomeningeal Disease

University of Alabama at Birmingham17 participantsStarted Feb 2019

Birmingham, Alabama, United States • San Francisco, California, United States • Washington D.C., District of Columbia, United States +6 more locations

RECRUITING< 1 mile

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

NCT05059444

The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and explore its value in a healthcare environment subject to cost containment.

Bladder CarcinomaUreter CarcinomaRenal Pelvis Carcinoma+13 more

Guardant Health, Inc.2,020 participantsStarted Sep 2021

Birmingham, Alabama, United States • Chandler, Arizona, United States • Hot Springs, Arkansas, United States +54 more locations

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Breast Cancer Trials in Other Cities

Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer

Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

Efficacy and Safety of 500mg of Fulvestrant

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Early Intervention

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors

FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

Assessing the Accuracy of Tumor Biopsies After Chemotherapy to Determine if Patients Can Avoid Breast Surgery

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC

A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

A Study of ADRX-0706 in Select Advanced Solid Tumors

Other Conditions in Boston